Cargando…

Treatment outcomes of standard (high dose) cisplatin and non‐standard chemotherapy for locally advanced head and neck cancer

INTRODUCTION: Concurrent chemoradiotherapy with high‐dose (HD) cisplatin is the standard treatment for locally advanced head and neck squamous cell carcinoma (LA‐HNSCC). Due to the higher treatment‐related adverse effects with standard therapy, alternative regimens (non‐standard therapy), namely, lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alamgeer, Muhammad, Coleman, Andrew, McDowell, Lachlan, Giddings, Charles, Safdar, Adnan, Sigston, Elizabeth, Wang, Yang, Subramaniam, Ashwin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875652/ https://www.ncbi.nlm.nih.gov/pubmed/35792145 http://dx.doi.org/10.1002/cnr2.1674

Ejemplares similares

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Dose to medium in head and neck radiotherapy: Clinical implications for target volume metrics
por: Hardcastle, Nicholas, et al.
Publicado: (2019)

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis
por: Lee, So Yeon, et al.
Publicado: (2018)

Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer
por: Gupta, Pramod Kumar, et al.
Publicado: (2016)

Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer
por: McDowell, Lachlan, et al.
Publicado: (2022)

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
por: Wolff, Hendrik Andreas, et al.
Publicado: (2008)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer
por: Ardizzoni, A, et al.
Publicado: (1999)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
por: Hu, Ming-Hung, et al.
Publicado: (2014)

Monitoring the compliance of the academic enterprise with the Fair Labor Standards Act
por: Bankston, Adriana, et al.
Publicado: (2017)

Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer
por: Chitapanarux, I, et al.
Publicado: (2010)

Combination of Taxanes, Cisplatin and Fluorouracil as Induction Chemotherapy for Locally Advanced Head and Neck Cancer: A Meta-Analysis
por: Qin, Hao, et al.
Publicado: (2012)

Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
por: Lu, Hsueh-Ju, et al.
Publicado: (2015)

Synchronous p16(+) nasopharyngeal and oropharyngeal squamous cell carcinoma: a case report and review
por: Ali, Muhammad, et al.
Publicado: (2021)

Prescribed dose versus calculated dose of spinal cord in standard head and neck irradiation assessed by 3-D plan
por: Majumder, Dipanjan, et al.
Publicado: (2014)

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients
por: Fayette, Jérôme, et al.
Publicado: (2016)

Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer
por: Garcia‐Soto, Arlene E., et al.
Publicado: (2021)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

Standards and Definitions in Neck Dissections of Differentiated Thyroid Cancer
por: Uludağ, Mehmet, et al.
Publicado: (2018)

A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Keam, Bhumsuk, et al.
Publicado: (2019)

Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies
por: Stein, Andrew P, et al.
Publicado: (2015)

Intensity standardization methods in magnetic resonance imaging of head and neck cancer
por: Wahid, Kareem A., et al.
Publicado: (2021)

Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study
por: Koramati, Samuel Luke, et al.
Publicado: (2021)

Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer
por: Han, Hye Ri, et al.
Publicado: (2021)

The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high‐dose cisplatin
por: Bril, Sandra I., et al.
Publicado: (2021)

Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report
por: Dieckmann, Klaus-Peter, et al.
Publicado: (2015)

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study
por: Hsieh, Ching-Yun, et al.
Publicado: (2020)

Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
por: Bae, Woo Kyun, et al.
Publicado: (2013)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

XIAP Is a Predictor of Cisplatin-Based Chemotherapy Response and Prognosis for Patients with Advanced Head and Neck Cancer
por: Yang, Xi-Hu, et al.
Publicado: (2012)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
por: Jacinto, Alexandre Arthur, et al.
Publicado: (2018)

Performance and standards for the process of head and neck cancer care: South and West audit of head and neck cancer 1996–1997 (SWAHN I)
por: Birchall, M A, et al.
Publicado: (2000)

COVID-19—An Opportunity for Optimizing Surveillance Protocols During and Beyond the Pandemic: HPV-Associated Oropharyngeal Cancer as an Example of Response-Based Local Surveillance
por: McDowell, Lachlan, et al.
Publicado: (2020)

Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas
por: Hoek, Jantien, et al.
Publicado: (2016)

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study
por: Visacri, Marília Berlofa, et al.
Publicado: (2017)

Effect of process standards on survival of patients with head and neck cancer in the south and west of England
por: Birchall, M, et al.
Publicado: (2004)

Phenotype Standardization of Angioedema in the Head and Neck Region Caused by Agents Acting on the Angiotensin System
por: Wadelius, M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_01r1o4qr0bb9m8vqmv2kojtiu0